Optimal latent TB control methods

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 3, 2005, Pages 236-

  Ridzon, Renée ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS INFECTION; LIVER TOXICITY; PATHOGENESIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 15344338839     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. CDC/ATS. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MWR Recomm Rep 2000; 49 (RR-6): 1-51.
2. Centers for Disease Control and Prevention. Update: adverse event data and revised Americian Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection-United States, 2003. MMWR 2003; 52: 735-739.
3. Tortajada C, Martínez-Lacasa J, Sánchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by human immunodeficiency virus? Int J Tuberc Lung Dis 2005; 9: 276-281.
4. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847.
5. Centers for Disease Control and Prevention. Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR 2002; 51 (10).